<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211887</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 02-0526</org_study_id>
    <secondary_id>02-0526</secondary_id>
    <secondary_id>CRC</secondary_id>
    <secondary_id>U01NS045719</secondary_id>
    <nct_id>NCT00211887</nct_id>
  </id_info>
  <brief_title>Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Lublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is for a randomized clinical trial (RCT) to determine if the combined use of interferon
      beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent
      used individually in patients with relapsing-remitting (RR) multiple sclerosis (MS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, double blind, randomized trial examining combination therapy versus
      single agent therapy with three-year follow-up on the last patient randomized. All patients
      will remain on therapy until the last patient completes the study. All patients will then be
      transitioned, based on the findings, to open label of combination with continued follow-up or
      some recommendation about single agent therapy. While the study design benefits from having
      two arms of single agent therapy to examine the important question of whether there are
      differences between the single agents, the primary interest is in combination therapy.
      Therefore, a two-group combination versus single agent concept was used - splitting the
      population into single agent and combination therapy equally. The single agent arm is divided
      into two groups, IFN and GA providing for 3 treatment arms: IFN intramuscularly (IM) and GA
      subcutaneously (SC) (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA
      SC and placebo IM (25% of the patients).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ARR - PDEs</measure>
    <time_frame>Baseline to Month 36</time_frame>
    <description>Annualized relapse rate of protocol-defined exacerbations Protocol defined relapse - an relapse seen within 7 days of onset, verified by the treating physician and independently observed as a change in EDSS by the examining physician. This relapse is defined as: the appearance of a new symptom or worsening of an old symptom, attributable to MS; accompanied by a change in the neurologic examination (defined as a 0.5 or greater increase in the EDSS over the last scheduled or unscheduled visit or a 2 point change in one functional system or a 1 point change in two functional systems, except bladder and cognitive changes); lasting at least 24 hours in the absence of fever; and preceded by stability or improvement for at least 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed Progression on the Expanded Disability Status Scale</measure>
    <time_frame>Baseline to Month 36</time_frame>
    <description>% with EDSS progression
Confirmed progression in a participant was defined as a 1.0 increase in the EDSS from baseline, when baseline &lt;=5.0; or an increase of 0.5 from baseline, when baseline &gt;=5.5, sustained for 6 months (2 successive quarterly visits), as assessed by the blinded EDSS examiner and confirmed centrally.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Multiple Sclerosis Functional Composite</measure>
    <time_frame>Baseline to month 36</time_frame>
    <description>positive indicates improvement
The Multiple Sclerosis Functional Composite (MSFC) is a scale measuring pyramidal functions, sensory functions, cerebellar functions, bowel &amp; bladder functions,brain stem functions, mental functions, and visual functions from 0 to 6.
0= normal 6= severe loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MRI Composite Score</measure>
    <time_frame>Baseline to month 36</time_frame>
    <description>MRI composite score (Z4 score) - the unweighted sum of the individual Z scores for enhanced tissue volume, T2 lesion burden, equivalence of the T1 hypointense lesion burden, normalized CSF (an inverse measure of atrophy with the appropriate sign so that all scores are directionally compatible - larger is worse) MRI enhancement status at baseline (0, 1-4, and 5 or more enhancing lesions)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1008</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Interferon beta 1-a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Interferon B1a Weekly vs. Placebo Glatiramer Acetate
Interferon b-1a (IFN) intramuscularly weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glatiramer acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo Interferon B1a Weekly vs. Active Glatiramer Acetate
Glatiramer acetate 20mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN and GA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Interferon B1a Weekly and Active Glatiramer Acetate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta 1-a</intervention_name>
    <description>The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).</description>
    <arm_group_label>Interferon beta 1-a</arm_group_label>
    <arm_group_label>IFN and GA</arm_group_label>
    <other_name>IFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glatiramer acetate</intervention_name>
    <description>The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).</description>
    <arm_group_label>glatiramer acetate</arm_group_label>
    <arm_group_label>IFN and GA</arm_group_label>
    <other_name>GA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>an inactive substance</description>
    <arm_group_label>Interferon beta 1-a</arm_group_label>
    <arm_group_label>glatiramer acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects between the ages of 18 and 60 years, inclusive.

          -  Diagnosis of relapsing-remitting MS by either the Poser or McDonald criteria.

          -  Expanded Disability Status Scale (EDSS) score between 0 and 5.5, inclusive.

          -  At least 2 exacerbations in the prior three years; one exacerbation may utilize the
             McDonald MRI criteria for dissemination in time (a new gadolinium [Gd]-enhancing
             lesion demonstrated on a scan done at least 3 months following onset of a clinical
             attack or a new T2 lesion or Gd-enhancing lesion on a follow-up scan after an
             additional 3 months).

          -  Give written informed consent prior to any testing under this protocol, including
             screening tests and evaluations that are not considered part of the subject's routine
             care.

        Exclusion Criteria:

          -  Any prior use of interferon beta or glatiramer acetate.

          -  Acute exacerbation within 30 days of screening.

          -  Steroids for acute exacerbations (&gt;100 mg/day) within 30 days of study entrance or
             chronic systemic steroid use.

          -  Evidence of progressive MS.

          -  Use IVIg, azathioprine, methotrexate, cyclosporine, mitoxantrone, cyclophosphamide,
             mycophenolate (CellCept) or plasma exchange in the twelve weeks prior to study drug
             dosing.

          -  Any previous treatment with natalizumab (Tysabri, Antegren), cladribine, T cell
             vaccine, Campath, daclizumab, rituximab, altered peptide ligand or total lymphoid
             irradiation.

          -  Treatment with 4 aminopyridines in the four weeks prior to study drug dosing.

          -  Prior treatment with any other investigational drug, unless approved by the Clinical
             Coordinating Center (Dr. Lublin).

          -  Inability to perform the baseline MSFC (timed 25-foot walk, 9-hole peg test [9HPT],
             and Paced Auditory Serial Addition Test 3 [PASAT3]).

          -  Inability to undergo baseline MRI scan.

          -  History of any significant cardiac, hepatic, pulmonary, or renal disease, immune
             deficiency, or other medical conditions that would preclude therapy with interferon
             beta, glatiramer acetate, or participation in this study.

          -  Known history of sensitivity to gadopentetate dimeglumine or mannitol.

          -  History of a seizure within the 3 months prior to randomization.

          -  History of suicidal ideation or an episode of severe depression within the 3 months
             prior to randomization.

          -  Abnormal screening blood tests exceeding any of the limits defined below:

               -  Alanine transaminase (ALT) or aspartate transaminase (AST) greater than two times
                  the upper limit of normal (i.e., &gt;2 × ULN)

               -  Total white blood cell count &lt;2,300/mm3

               -  Platelet count &lt;80,000/mm3

               -  Creatinine &gt;2 × ULN

          -  Participation in another experimental clinical trial, without formal approval.

          -  History of alcohol or drug abuse within the 2 years prior to randomization.

          -  Female subjects who are currently pregnant, breast-feeding, or plan to become
             pregnant.

          -  For female subjects, unless postmenopausal or surgically sterile, unwillingness to
             practice effective contraception, as defined by the investigator, during the study.
             The rhythm method is not to be used as the sole method of contraception.

          -  Unwillingness or inability to comply with the requirements of this protocol including
             the presence of any condition that is likely to affect the subject's returning for
             scheduled follow-up visits on schedule (any physical, mental, or social condition).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Lublin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrow Neurology Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Neurospecialists PLLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter East Bay Medical Group</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Center North Orange County</name>
      <address>
        <city>La Habra</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA West Los Angeles Healthcare Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Clinical Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patricia Fodor P.C.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, PA</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami - Neurology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shepherd Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Neurology - Multiple Sclerosis Center</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois College of Medicine</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruan Neurology Clinic and Research Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Center for MS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts-New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinic - MS Center</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University - St. Louis VA</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Rockies MS Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Medical School</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraState Medical Center</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Associates of Albany, PC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jacobs Neurological Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop Neurology Faculty Practice</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Hospital For Joint Diseases</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Shore Neurologic Associates Inc.</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMC-Neuroscience &amp; Spine Institute, Division of Neurology, MS Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meritcare Neuroscience</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroCare Center, Inc.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Specialists</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College Of Ohio</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oak Clinic for Multiple Sclerosis</name>
      <address>
        <city>Uniontown</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny MS Treatment Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Research Center, Inc.</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Associates, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center at Evergreen</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional MS Center at St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Health and the University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital-Multiple Sclerosis Research Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS; CombiRx Investigators. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013 Mar;73(3):327-40. doi: 10.1002/ana.23863. Epub 2013 Mar 11.</citation>
    <PMID>23424159</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>June 25, 2013</results_first_submitted>
  <results_first_submitted_qc>March 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 3, 2014</results_first_posted>
  <last_update_submitted>March 6, 2014</last_update_submitted>
  <last_update_submitted_qc>March 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Fred Lublin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>treatment trial</keyword>
  <keyword>autoimmune disease</keyword>
  <keyword>Relapsing Remitting</keyword>
  <keyword>MS Treatment</keyword>
  <keyword>interferon beta-1a</keyword>
  <keyword>glatiramer acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Glatiramer Acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial enrolled participants from January 2005 through April 2009. The trial was conducted in 68 sites, both private practice and academic, in the USA and Canada.</recruitment_details>
      <pre_assignment_details>1129 participants assessed for eligibility. 121 excluded due to recent activity (16), &lt;2 exacerbations (14), other medical exclusions (14), inconclusive for RRMS (12), abnormal lab value (10), cannot have Gd (5), EDSS&gt;5.5 (2), and other reason (46).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IFN + GA</title>
          <description>Interferon beta-1a 30µg intramuscularly weekly and glatiramer acetate (GA) 20mg daily</description>
        </group>
        <group group_id="P2">
          <title>Interferon Beta 1a</title>
          <description>Interferon beta-1a 30µg intramuscularly weekly</description>
        </group>
        <group group_id="P3">
          <title>Glatiramer Acetate</title>
          <description>glatiramer acetate 20mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="499"/>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="259"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="397"/>
                <participants group_id="P2" count="194"/>
                <participants group_id="P3" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-medical reason</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other medical reason</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Side effects</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IFN + GA</title>
          <description>Interferon beta-1a intramuscularly weekly and glatiramer acetate daily</description>
        </group>
        <group group_id="B2">
          <title>IFB-1a</title>
          <description>Interferon beta-1a</description>
        </group>
        <group group_id="B3">
          <title>Glatiramer</title>
          <description>glatiramer acetate</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="499"/>
            <count group_id="B2" value="250"/>
            <count group_id="B3" value="259"/>
            <count group_id="B4" value="1008"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="9.4"/>
                    <measurement group_id="B2" value="37.6" spread="10.2"/>
                    <measurement group_id="B3" value="39.0" spread="9.5"/>
                    <measurement group_id="B4" value="37.7" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="372"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ARR - PDEs</title>
        <description>Annualized relapse rate of protocol-defined exacerbations Protocol defined relapse – an relapse seen within 7 days of onset, verified by the treating physician and independently observed as a change in EDSS by the examining physician. This relapse is defined as: the appearance of a new symptom or worsening of an old symptom, attributable to MS; accompanied by a change in the neurologic examination (defined as a 0.5 or greater increase in the EDSS over the last scheduled or unscheduled visit or a 2 point change in one functional system or a 1 point change in two functional systems, except bladder and cognitive changes); lasting at least 24 hours in the absence of fever; and preceded by stability or improvement for at least 30 days.</description>
        <time_frame>Baseline to Month 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IFN + GA</title>
            <description>Interferon beta-1a intramuscularly weekly and glatiramer acetate daily</description>
          </group>
          <group group_id="O2">
            <title>IFB-1a</title>
            <description>Interferon beta-1a</description>
          </group>
          <group group_id="O3">
            <title>Glatiramer</title>
            <description>glatiramer acetate</description>
          </group>
        </group_list>
        <measure>
          <title>ARR - PDEs</title>
          <description>Annualized relapse rate of protocol-defined exacerbations Protocol defined relapse – an relapse seen within 7 days of onset, verified by the treating physician and independently observed as a change in EDSS by the examining physician. This relapse is defined as: the appearance of a new symptom or worsening of an old symptom, attributable to MS; accompanied by a change in the neurologic examination (defined as a 0.5 or greater increase in the EDSS over the last scheduled or unscheduled visit or a 2 point change in one functional system or a 1 point change in two functional systems, except bladder and cognitive changes); lasting at least 24 hours in the absence of fever; and preceded by stability or improvement for at least 30 days.</description>
          <units>relapses per year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="499"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12"/>
                    <measurement group_id="O2" value="0.16"/>
                    <measurement group_id="O3" value="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confirmed Progression on the Expanded Disability Status Scale</title>
        <description>% with EDSS progression
Confirmed progression in a participant was defined as a 1.0 increase in the EDSS from baseline, when baseline &lt;=5.0; or an increase of 0.5 from baseline, when baseline &gt;=5.5, sustained for 6 months (2 successive quarterly visits), as assessed by the blinded EDSS examiner and confirmed centrally.</description>
        <time_frame>Baseline to Month 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IFN + GA</title>
            <description>Interferon beta-1a intramuscularly weekly and glatiramer acetate daily</description>
          </group>
          <group group_id="O2">
            <title>IFB-1a</title>
            <description>Interferon beta-1a</description>
          </group>
          <group group_id="O3">
            <title>Glatiramer</title>
            <description>glatiramer acetate</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Progression on the Expanded Disability Status Scale</title>
          <description>% with EDSS progression
Confirmed progression in a participant was defined as a 1.0 increase in the EDSS from baseline, when baseline &lt;=5.0; or an increase of 0.5 from baseline, when baseline &gt;=5.5, sustained for 6 months (2 successive quarterly visits), as assessed by the blinded EDSS examiner and confirmed centrally.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="499"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" spread="1.2"/>
                    <measurement group_id="O2" value="21.6" spread="1.2"/>
                    <measurement group_id="O3" value="24.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Multiple Sclerosis Functional Composite</title>
        <description>positive indicates improvement
The Multiple Sclerosis Functional Composite (MSFC) is a scale measuring pyramidal functions, sensory functions, cerebellar functions, bowel &amp; bladder functions,brain stem functions, mental functions, and visual functions from 0 to 6.
0= normal 6= severe loss</description>
        <time_frame>Baseline to month 36</time_frame>
        <population>Due to participant dropouts, there were less participants analyzed for this particular outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN + GA</title>
            <description>Interferon beta-1a intramuscularly weekly and glatiramer acetate daily</description>
          </group>
          <group group_id="O2">
            <title>IFB-1a</title>
            <description>Interferon beta-1a</description>
          </group>
          <group group_id="O3">
            <title>Glatiramer</title>
            <description>glatiramer acetate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Multiple Sclerosis Functional Composite</title>
          <description>positive indicates improvement
The Multiple Sclerosis Functional Composite (MSFC) is a scale measuring pyramidal functions, sensory functions, cerebellar functions, bowel &amp; bladder functions,brain stem functions, mental functions, and visual functions from 0 to 6.
0= normal 6= severe loss</description>
          <population>Due to participant dropouts, there were less participants analyzed for this particular outcome measure.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5" lower_limit="-3.5" upper_limit="2.3"/>
                    <measurement group_id="O2" value="0.1" spread="0.5" lower_limit="-2.0" upper_limit="1.8"/>
                    <measurement group_id="O3" value="0.2" spread="0.5" lower_limit="-3.0" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in MRI Composite Score</title>
        <description>MRI composite score (Z4 score) - the unweighted sum of the individual Z scores for enhanced tissue volume, T2 lesion burden, equivalence of the T1 hypointense lesion burden, normalized CSF (an inverse measure of atrophy with the appropriate sign so that all scores are directionally compatible – larger is worse) MRI enhancement status at baseline (0, 1-4, and 5 or more enhancing lesions)</description>
        <time_frame>Baseline to month 36</time_frame>
        <population>Due to participant dropouts, there were less participants analyzed for this particular outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>IFN + GA</title>
            <description>Interferon beta-1a intramuscularly weekly and glatiramer acetate daily</description>
          </group>
          <group group_id="O2">
            <title>IFB-1a</title>
            <description>Interferon beta-1a</description>
          </group>
          <group group_id="O3">
            <title>Glatiramer</title>
            <description>glatiramer acetate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MRI Composite Score</title>
          <description>MRI composite score (Z4 score) - the unweighted sum of the individual Z scores for enhanced tissue volume, T2 lesion burden, equivalence of the T1 hypointense lesion burden, normalized CSF (an inverse measure of atrophy with the appropriate sign so that all scores are directionally compatible – larger is worse) MRI enhancement status at baseline (0, 1-4, and 5 or more enhancing lesions)</description>
          <population>Due to participant dropouts, there were less participants analyzed for this particular outcome measure.</population>
          <units>z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="1.30"/>
                    <measurement group_id="O2" value="0.05" spread="1.27"/>
                    <measurement group_id="O3" value="0.10" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were only collected with regard to the affected organ system.</desc>
      <group_list>
        <group group_id="E1">
          <title>IFN + GA</title>
          <description>Interferon beta-1a intramuscularly weekly and glatiramer acetate daily</description>
        </group>
        <group group_id="E2">
          <title>IFB-1a</title>
          <description>Interferon beta-1a</description>
        </group>
        <group group_id="E3">
          <title>Glatiramer</title>
          <description>glatiramer acetate</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="499"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="499"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepato-biliary disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="499"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal, connective tissue and bone disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="499"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign and malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="499"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="499"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="499"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="499"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="499"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="499"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="29" subjects_affected="23" subjects_at_risk="499"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="250"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="499"/>
                <counts group_id="E2" events="27" subjects_affected="21" subjects_at_risk="250"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>GI Upset</sub_title>
                <counts group_id="E1" events="44" subjects_affected="41" subjects_at_risk="499"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="499"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="250"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="99" subjects_affected="81" subjects_at_risk="499"/>
                <counts group_id="E2" events="53" subjects_affected="40" subjects_at_risk="250"/>
                <counts group_id="E3" events="51" subjects_affected="42" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" events="86" subjects_affected="64" subjects_at_risk="499"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="250"/>
                <counts group_id="E3" events="35" subjects_affected="26" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="499"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="250"/>
                <counts group_id="E3" events="24" subjects_affected="22" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="213" subjects_affected="139" subjects_at_risk="499"/>
                <counts group_id="E2" events="101" subjects_affected="69" subjects_at_risk="250"/>
                <counts group_id="E3" events="122" subjects_affected="75" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="120" subjects_affected="79" subjects_at_risk="499"/>
                <counts group_id="E2" events="44" subjects_affected="32" subjects_at_risk="250"/>
                <counts group_id="E3" events="68" subjects_affected="46" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="39" subjects_affected="34" subjects_at_risk="499"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" events="148" subjects_affected="99" subjects_at_risk="499"/>
                <counts group_id="E2" events="86" subjects_affected="53" subjects_at_risk="250"/>
                <counts group_id="E3" events="84" subjects_affected="51" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" events="106" subjects_affected="64" subjects_at_risk="499"/>
                <counts group_id="E2" events="64" subjects_affected="37" subjects_at_risk="250"/>
                <counts group_id="E3" events="56" subjects_affected="37" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergies (Environmental or Seasonal)</sub_title>
                <counts group_id="E1" events="39" subjects_affected="29" subjects_at_risk="499"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="250"/>
                <counts group_id="E3" events="20" subjects_affected="18" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="54" subjects_affected="44" subjects_at_risk="499"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E3" events="30" subjects_affected="22" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="358" subjects_affected="197" subjects_at_risk="499"/>
                <counts group_id="E2" events="172" subjects_affected="102" subjects_at_risk="250"/>
                <counts group_id="E3" events="172" subjects_affected="98" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="499"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="250"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Flu/Flu Like Symptoms</sub_title>
                <counts group_id="E1" events="122" subjects_affected="98" subjects_at_risk="499"/>
                <counts group_id="E2" events="62" subjects_affected="51" subjects_at_risk="250"/>
                <counts group_id="E3" events="52" subjects_affected="44" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>GI Virus</sub_title>
                <counts group_id="E1" events="35" subjects_affected="33" subjects_at_risk="499"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="250"/>
                <counts group_id="E3" events="32" subjects_affected="30" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="63" subjects_affected="46" subjects_at_risk="499"/>
                <counts group_id="E2" events="27" subjects_affected="20" subjects_at_risk="250"/>
                <counts group_id="E3" events="46" subjects_affected="25" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="58" subjects_affected="47" subjects_at_risk="499"/>
                <counts group_id="E2" events="37" subjects_affected="36" subjects_at_risk="250"/>
                <counts group_id="E3" events="40" subjects_affected="32" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Joint Pain/Stiffness</sub_title>
                <counts group_id="E1" events="44" subjects_affected="40" subjects_at_risk="499"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="250"/>
                <counts group_id="E3" events="29" subjects_affected="27" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive Difficulties</sub_title>
                <counts group_id="E1" events="33" subjects_affected="26" subjects_at_risk="499"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="43" subjects_affected="37" subjects_at_risk="499"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="250"/>
                <counts group_id="E3" events="22" subjects_affected="17" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Extremity Pain/Soreness/Stiffness</sub_title>
                <counts group_id="E1" events="105" subjects_affected="81" subjects_at_risk="499"/>
                <counts group_id="E2" events="61" subjects_affected="41" subjects_at_risk="250"/>
                <counts group_id="E3" events="68" subjects_affected="51" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Extremity Weakness</sub_title>
                <counts group_id="E1" events="34" subjects_affected="26" subjects_at_risk="499"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="250"/>
                <counts group_id="E3" events="22" subjects_affected="18" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="116" subjects_affected="88" subjects_at_risk="499"/>
                <counts group_id="E2" events="50" subjects_affected="40" subjects_at_risk="250"/>
                <counts group_id="E3" events="65" subjects_affected="47" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Paresthesias</sub_title>
                <counts group_id="E1" events="46" subjects_affected="39" subjects_at_risk="499"/>
                <counts group_id="E2" events="42" subjects_affected="28" subjects_at_risk="250"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Unspecified Neuropathic Symptoms</sub_title>
                <counts group_id="E1" events="146" subjects_affected="103" subjects_at_risk="499"/>
                <counts group_id="E2" events="92" subjects_affected="58" subjects_at_risk="250"/>
                <counts group_id="E3" events="67" subjects_affected="45" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety/Panic Attacks</sub_title>
                <counts group_id="E1" events="48" subjects_affected="41" subjects_at_risk="499"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="250"/>
                <counts group_id="E3" events="24" subjects_affected="22" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="103" subjects_affected="88" subjects_at_risk="499"/>
                <counts group_id="E2" events="50" subjects_affected="40" subjects_at_risk="250"/>
                <counts group_id="E3" events="51" subjects_affected="43" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary/Bladder Issues</sub_title>
                <counts group_id="E1" events="57" subjects_affected="44" subjects_at_risk="499"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="250"/>
                <counts group_id="E3" events="25" subjects_affected="22" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dental Abcess/Extraction/Procedure</sub_title>
                <counts group_id="E1" events="53" subjects_affected="43" subjects_at_risk="499"/>
                <counts group_id="E2" events="24" subjects_affected="18" subjects_at_risk="250"/>
                <counts group_id="E3" events="40" subjects_affected="33" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="74" subjects_affected="57" subjects_at_risk="499"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="250"/>
                <counts group_id="E3" events="25" subjects_affected="22" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>absence of a comparative randomized placebo only group</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Fred D. Lublin</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-6854</phone>
      <email>fred.lublin@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

